1 – 10 of 17
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
(
- Contribution to journal › Article
- 2021
-
Mark
Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors
(
- Contribution to journal › Article
- 2018
-
Mark
A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk
2018) In Clinical cancer research : an official journal of the American Association for Cancer Research 24(23). p.5895-5901(
- Contribution to journal › Article
- 2017
-
Mark
Nålbiopsi är inte bästa metod för att diagnostisera lymfom : Den ökade användningen kan ge allvarliga konsekvenser för diagnostik, forskning och behandlingsutveckling
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Estrogen receptor β1 in diffuse large B-cell lymphoma growth and as a prognostic biomarker
(
- Contribution to journal › Article
- 2015
-
Mark
The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
(
- Contribution to journal › Article
-
Mark
Satisfactory outcome after intensive chemotherapy with pragmatic use of minimal residual disease (MRD) monitoring in older patients with Philadelphia-negative B cell precursor acute lymphoblastic leukaemia: a Swedish registry-based study
(
- Contribution to journal › Article
- 2014
-
Mark
The Target for Statins, HMG-CoA Reductase, Is Expressed in Ductal Carcinoma-In Situ and May Predict Patient Response to Radiotherapy.
(
- Contribution to journal › Article
-
Mark
High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden
(
- Contribution to journal › Article
- 2013
-
Mark
A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ.
(
- Contribution to journal › Article